Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-Rodatristat Ethyl in Healthy Males
NCT05006118Phase 1Completed
- Sponsor
- Altavant Sciences
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rodatristat in pulmonary arterial hypertension (PAH), sponsored by Altavant Sciences. Primary endpoint: Overall, urinary, and fecal recovery of total radioactivity as a percentage of administered dose at 15 days. Started Sep 2021; status: completed.
02
Drugs
rodatristat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05006118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006118.